Due to its usefulness as a prognostic biomarker and for targeted therapy, HER2 amplification in BC is routinely tested for in clinical laboratories (tumors being classified as amplified ‘HER2+’ or non-amplified ‘HER2-’). This evidence concerns the gene ERBB2 and breast cancer.